Chimeric Therapeutics (ASX:CHM)
We spoke to Dr Rebecca McQualter, CEO of Chimeric Therapeutics (ASX:CHM), about the company’s great prospects with CHM 2101, which was in-licensed from the University of Pennsylvania in 2021.
The product represents a ‘third generation’ CAR-T that uses lentivirus as the delivery vector. The clinical data from a Phase 1/2 study in colorectal cancer, gastric cancer and Neuroendocrine Tumours has been very encouraging.
As of mid-November 2025, six of the eight evaluable subjects from Doses 1 and 2 had achieved disease control at 28 days and five of those six had ongoing stable disease beyond the 20 days. We venture to say that Chimeric Therapeutics is headed for the CAR-T ‘Big Time’.
Looking for the Best ASX Life Sciences stocks to invest in right now?
